Drug intelligence / Profile preview

poziotinib + paclitaxel + trastuzumab

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral (poziotinib), Intravenous (paclitaxel, Trastuzumab)

Overview

Poziotinib + paclitaxel + trastuzumab is an investigational combination therapy composed of three agents: poziotinib, a potent irreversible pan-HER tyrosine kinase inhibitor that targets EGFR, HER2 (ERBB2), and HER4 (ERBB4); paclitaxel, a microtubule stabilizing antineoplastic agent; and trastuzumab, a monoclonal antibody targeting the HER2 extracellular domain. This combination is primarily studied for the treatment of HER2-positive advanced gastric cancer, with poziotinib enhancing the efficacy of paclitaxel and trastuzumab by irreversibly inhibiting HER-family signaling pathways and overcoming resistance mechanisms via inhibition of ABCB1-mediated drug efflux. Paclitaxel disrupts microtubule dynamics and mitosis, while trastuzumab inhibits HER2 signaling, leading to growth arrest and apoptosis in HER2-overexpressing tumors.

Brand names: Herceptin (trastuzumab)Taxol (paclitaxel)
Other names: poziotinib + paclitaxel + trastuzumab

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))ERBB4 (Erb-b2 receptor tyrosine kinase 4)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on poziotinib + paclitaxel + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on poziotinib + paclitaxel + trastuzumab.

Explore the full profile